PRX-080665-HT2BR antagonist CAS# 866206-54-4 |
- Piceatannol
Catalog No.:BCN5824
CAS No.:10083-24-6
- R788 disodium
Catalog No.:BCC3695
CAS No.:1025687-58-4
- GS-9973
Catalog No.:BCC5278
CAS No.:1229208-44-9
- R406 (free base)
Catalog No.:BCC2553
CAS No.:841290-80-0
- Fostamatinib (R788)
Catalog No.:BCC5082
CAS No.:901119-35-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 866206-54-4 | SDF | Download SDF |
| PubChem ID | 11502243 | Appearance | Powder |
| Formula | C19H17ClFN5S | M.Wt | 401.89 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 7 mg/mL (17.42 mM; Need ultrasonic) | ||
| Chemical Name | 5-[[4-[(6-chlorothieno[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]-2-fluorobenzonitrile | ||
| SMILES | C1CN(CCC1NC2=C3C=C(SC3=NC=N2)Cl)CC4=CC(=C(C=C4)F)C#N | ||
| Standard InChIKey | IENZFHBNCRQMNP-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C19H17ClFN5S/c20-17-8-15-18(23-11-24-19(15)27-17)25-14-3-5-26(6-4-14)10-12-1-2-16(21)13(7-12)9-22/h1-2,7-8,11,14H,3-6,10H2,(H,23,24,25) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
PRX-08066 Dilution Calculator
PRX-08066 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4882 mL | 12.4412 mL | 24.8824 mL | 49.7649 mL | 62.2061 mL |
| 5 mM | 0.4976 mL | 2.4882 mL | 4.9765 mL | 9.953 mL | 12.4412 mL |
| 10 mM | 0.2488 mL | 1.2441 mL | 2.4882 mL | 4.9765 mL | 6.2206 mL |
| 50 mM | 0.0498 mL | 0.2488 mL | 0.4976 mL | 0.9953 mL | 1.2441 mL |
| 100 mM | 0.0249 mL | 0.1244 mL | 0.2488 mL | 0.4976 mL | 0.6221 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
PRX-08066 is a selective antagonist of 5-hydroxytryptamine receptor 2B (5-HT2BR) with Ki value of 3.4nM [1].
PRX-08066 is found to causes selective vasodilation of pulmonary arteries and is developed to treat for pulmonary arterial hypertension (PAH). In the in vitro studies, PRX-08066 shows effects on the vascular muscularization induced by 5-HT. It inhibits 5-HT induced mitogen-activated protein kinase activation with IC50 value of 12nM. In addition, it significantly reduces thymidine incorporation in CHO cells expressing human 5-HT2BR with IC50 value of 3nM. In both mice and rat models, PRX-08066 reverses the hypoxia-dependent increase in right ventricular systolic pressure. Besides that, PRX-08066 is also found to have anti-proliferative and anti-fibrotic effects. It inhibits the secretion of 5-HT, the phosphorylation of ERK1/2 and synthesis of profibrotic growth factor. Moreover, PRX-08066 inhibits the proliferation of the small intestinal neuroendocrine tumor cell line KRJ-I with IC50 value of 4.6nM [1, 2].
References:
[1] Porvasnik S L, Germain S, Embury J, et al. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats. Journal of Pharmacology and Experimental Therapeutics, 2010, 334(2): 364-372.
[2] Svejda B, Kidd M, Giovinazzo F, et al. The 5-HT2B receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment. Cancer, 2010, 116(12): 2902-2912.
- Clausine Z
Catalog No.:BCN4414
CAS No.:866111-14-0
- 6-Benzoyl-5,7-dihydroxy-2,2-dimethylchromane
Catalog No.:BCN1326
CAS No.:86606-14-6
- L-745,870 trihydrochloride
Catalog No.:BCC5695
CAS No.:866021-03-6
- Oleuropeic acid 8-O-glucoside
Catalog No.:BCN4025
CAS No.:865887-46-3
- Tideglusib
Catalog No.:BCC4511
CAS No.:865854-05-3
- Isochamaejasmenin B
Catalog No.:BCN3045
CAS No.:865852-48-8
- Chamaejasmenin D
Catalog No.:BCN3046
CAS No.:865852-47-7
- RX-3117
Catalog No.:BCC6381
CAS No.:865838-26-2
- Cytochrome c - pigeon (88-104)
Catalog No.:BCC1038
CAS No.:86579-06-8
- PF-03084014
Catalog No.:BCC1848
CAS No.:865773-15-5
- Trelagliptin
Catalog No.:BCC2014
CAS No.:865759-25-7
- 2-[(6-Chloro-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl)methyl]benzonitrile
Catalog No.:BCC8506
CAS No.:865758-96-9
- PRX-08066 Maleic acid
Catalog No.:BCC1165
CAS No.:866206-55-5
- 3,4,5-Tricaffeoylquinic acid
Catalog No.:BCN2384
CAS No.:86632-03-3
- Xanthiside
Catalog No.:BCN2545
CAS No.:866366-86-1
- 7-Ethyl-10-Hydroxycamptothecin
Catalog No.:BCN2479
CAS No.:86639-52-3
- 10-Aminocamptothecin
Catalog No.:BCC8111
CAS No.:86639-63-6
- DPPI 1c hydrochloride
Catalog No.:BCC2363
CAS No.:866396-34-1
- Dorsomorphin
Catalog No.:BCC5131
CAS No.:866405-64-3
- 7-Hydroxy-3-prenylcoumarin
Catalog No.:BCN4415
CAS No.:86654-26-4
- [Ala2,8,9,11,19,22,24,25,27,28]-VIP
Catalog No.:BCC5973
CAS No.:866552-34-3
- Yuexiandajisu D
Catalog No.:BCN3774
CAS No.:866556-15-2
- Yuexiandajisu E
Catalog No.:BCN3775
CAS No.:866556-16-3
- (1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutane hydrochloride
Catalog No.:BCC8383
CAS No.:866783-13-3
PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.[Pubmed:20430844]
J Pharmacol Exp Ther. 2010 Aug;334(2):364-72.
Pulmonary arterial hypertension (PAH) is a life-threatening disease that results in right ventricular failure. 5-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)-2-fluorobe nzonitrile monofumarate (PRX-08066) is a selective 5-hydroxytryptamine receptor 2B (5-HT2BR) antagonist that causes selective vasodilation of pulmonary arteries. In the current study, the effects of PRX-08066 were assessed by using the monocrotaline (MCT)-induced PAH rat model. Male rats received 40 mg/kg MCT or phosphate-buffered saline and were treated orally twice a day with vehicle or 50 or 100 mg/kg PRX-08066 for 5 weeks. Pulmonary and cardiac functions were evaluated by hemodynamics, heart weight, magnetic resonance imaging (MRI), pulmonary artery (PA) morphology, and histology. Cardiac MRI demonstrated that PRX-08066 (100 mg/kg) significantly (P < 0.05) improved right ventricular ejection fraction. PRX-08066 significantly reduced peak PA pressure at 50 and 100 mg/kg (P < 0.05 and < 0.01, respectively) compared with MCT control animals. PRX-08066 therapy also significantly reduced right ventricle (RV)/body weight and RV/left ventricle + septum (P < 0.01 and < 0.001, respectively) compared with MCT-treated animals. Morphometric assessment of pulmonary arterioles revealed a significant reduction in medial wall thickening and lumen occlusion associated with both doses of PRX-08066 (P < 0.01). The 5-HT2BR antagonist PRX-08066 significantly attenuated the elevation in PA pressure and RV hypertrophy and maintained cardiac function. Pulmonary vascular remodeling was also diminished compared with MCT control rats. PRX-08066 prevents the severity of PAH in the MCT rat model.
